News & Media
Apr 01st
Following approval of shareholders, companies sign German transfer agreement
Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH are now wholly owned by OpGen, Inc.
OpGen consideration shares to be distributed to Curetis N.V. shareholders and Curetis N.V. to be dissolved and delisted from Euronext
Three Curetis N.V. Supervisory Board members resign to join newly formed OpGen Inc. board of directors
Mar 16th
Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours
Test kit to be made available via Curetis’ European sales channels
Synergies with Curetis Unyvero HPN panel for pneumonia testing for bacterial co-infections in Covid-19 patients
Mar 10th
Curetis N.V. reports that a Special Meeting of shareholders of OpGen, Inc. held today, March 10, 2020, in Washington DC, USA, to approve the business combination of Curetis and OpGen, was adjourned.
News Archives
Apr 01 – Curetis and OpGen Close Business Combination
Mar 16th – Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe
Mar 10th – Curetis N.V. Updates on OpGen, Inc. Special Shareholders’ Meeting Held on March 10, 2020
Mar 10th – Curetis N.V. Reports Results of the Extraordinary General Meeting Held on March 10, 2020
Feb 06th – Curetis and Quaphaco Enter Into Unyvero Distribution Partnership for Vietnam
Jan 27th – Curetis to Hold Extraordinary General Meeting on March 10,2020
Jan 23rd – Curetis To Attend Key Conferences in the First Half of 2020
Jan 14th – Curetis Launches Unyvero LRT Panel for BAL Specimen in the U.S.
Dec 20th – Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
Dec 10 – Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and AWS Activate Programs
Nov 25 – Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize
Nov 25 – Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens
Nov 25 – Curetis Publishes Third Quarter and 9-Month Business and Financial update
Oct 30 – Curetis To Attend Key Conferences in the Fourth Quarter of 2019
Oct 28 – Curetis Group Company Ares Genetics launches AI-Powered Molecular Antibiotic Susceptibility Test
Sep 18 – Curetis Reports Financial Results for the First Six Months of 2019
Sep 04 – Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
Aug 12 – Curetis Retains H.C. Wainwright & Co. as Strategic Advisor
Jul 30 – Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region
Jul 25 – Curetis To Present at Solebury Trout European Biotech Investor Day in NYC
Jul 23 – Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
Jul 04 – Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing
Jul 02 – Curetis To Attend Key Conferences in the Third Quarter of 2019
Jun 28 – Curetis Reports Results of the Annual General Meeting Held on June 27, 2019
Jun 04 – New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019
May 21 – Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
May 17 – Curetis Announces Financial Results for the first Three Months of 2019
May 15 – Curetis to Hold Annual General Shareholders’ Meeting on June 27,2019
Apr 11 – Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019
Apr 05 – Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019
Apr 04 – Curetis: Study Data Presented at ECCMID 2019 Confirm Clinical Beneftis of Unyvero Platform
Apr 01 – Curetis To Attend Key Conferences in the Second Quarter of 2019
Feb 04 – Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China
Jan 30 – Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand
Dec 13 – Curetis Sharpens Focus on Near-Term Strategic Value Drivers
Nov 23 – Curetis Announces Financial Results for the First Nine Months of 2018
Nov 23 – Curetis Accelerates 510(k) Submission Preparation for Unyvero
Oct 11 – Curetis, Beijing Clear Biotech Expand Strategic Collaboration for Unyvero in Greater China
Oct 02 – Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
Sep 28 – Curetis Publishes Interim Report for the First Half-Year 2018
Sep 17 – Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018
Sep 04 – Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test
Aug 14 – Curetis Announces Change in Curetis USA Inc. Management
Aug 14 – Curetis Announces Financial Results for the First Six Months of 2018
Aug 07 – Curetis to Report its Half-Year Results 2018 on August 14, 2018
Aug 07 – Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets
Jul 31 – Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
Jun 21 – Curetis Reports Results of the Annual General Meeting Held on June 21, 2018
Jun 12 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2018
Jun 07 – Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.
May 18 – Curetis Publishes Business and Financial Update for the First Quarter 2018
May 09 – Curetis to Hold Annual General Shareholders’ Meeting on June 21, 2018
Apr 30 – Curetis Announces Change of the Composition of Its Supervisory Board
Apr 30 – Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
Apr 23 – Curetis to Publish its 2017 Annual Results on April 30, 2018
Apr 19 – Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
Apr 18 – Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
Apr 11 – Curetis Establishes U.S. Scientific Advisory Board
Mar 26 – Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018
Mar 14 – Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
Mar 06 – Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
Jan 10 – Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
Jan 08 – Curetis Expects Near-Term FDA Decision on De Novo Request
Dec 19 – Curetis To Attend Key Investor and Scientific Conferences In The First Quarter 2018
Nov 16 – Curetis Publishes Business and Financial Update for the First Nine Months of 2017
Oct 23 – Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
Oct 06 – Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017
Sep 12 – MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
Aug 16 – Curetis Announces Financial Results for the First Six Months of 2017
Aug 16 – Curetis Announces Management Board Changes
Aug 04 – Curetis to Report its Half-Year Results 2017 on August 16, 2017
Jul 07 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017
Jun 23 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017
May 24 – Curetis Provides Business and Financial Update for the First Quarter 2017
May 24 – Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
May 08 – Curetis to Hold Annual General Shareholders’ Meeting on June 23, 2017
Apr 20 – Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking
Apr 12 – Curetis Expands Supervisory and Medical Advisory Boards
Apr 12 – Curetis Reports Full-Year 2016 Financial Results and Updates 2017 Guidance
Apr 10 – Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe
Apr 06 – Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing
Apr 04 – Curetis to Publish its Annual Results 2016 on April 12, 2017
Mar 08 – Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech
Jan 31 – Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers
Jan 05 – Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge
Jan 04 – Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017
Jan 04 – Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections
Dec 13 – Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec
Nov 18 – Curetis Publishes Business and Financial Update for the First Nine Months 2016
Oct 25 – Curetis Announces Positive Top Line Data from U.S. FDA Trial
Oct 04 – Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016
Sep 07 – Curetis to host conference call and webcast on GEAR acquisition
Sep 06 – Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge
Aug 19 – Curetis Reports Financial Results for the First Six Months of 2016
Aug 01 – Curetis to Report its Half-Year Results 2016 on August 19, 2016
Jul 05 – Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary
Jun 28 – Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections
Jun 17 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 16, 2016
Jun 06 – Curetis and Axonlab sign multi-market European distribution agreement
May 20 – Curetis Publishes First Quarter 2016 Business and Financial Update
May 02 – Curetis shall hold its Annual General Shareholders’ Meeting on June 16, 2016
Apr 12 – Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance
Mar 24 – Curetis Announces Participation in Several Investor and Industry Conferences in Q2-2016
Mar 24 – Curetis to Publish its Annual Results 2015 on April 12, 2016
Mar 23 – Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016
Feb 23 – Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge
Feb 03 – Curetis Expands Commercial Team
Jan 11 – Curetis Establishes Medical Advisory Board with Internationally Renowned Experts
Jan 05 – Curetis Announces Participation in Several Investor and Industry Conferences
Dec 03 – Curetis Announces the Exercise of the Over-Allotment Option
Nov 10 – Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million
Oct 29 – Curetis Announces New Supervisory Board of Curetis N.V.
Oct 28 – Curetis Announces its Initial Public Offering on Euronext in Amsterdam and Euronext in Brussels
Oct 05 – Curetis and Acumen to Collaborate on Unyvero Sepsis Test and ASEAN Distribution
Sep 25 – Curetis Enters into Distribution Agreement to Expand Commercial Activities into Greater China
Jul 08 – Curetis Initiates Next Phase of Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections
Jun 24 – Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial
May 11 – Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer
Apr 20 – Curetis Expands Commercial Organization
Apr 16 – Curetis to Launch Next-Generation Pneumonia Application at ECCMID 2015
Mar 9 – Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application
Feb 17 – Curetis Presents Product Updates at Intensive Care Conference
Nov 24 – Curetis Closes EUR 14.5 Million Extension of Series B Financing
Oct 09 – Curetis Joins European Prosthetic Joint Infection Cohort Study (EPJIC)
Sep 30 – Curetis Presents New Unyvero Pneumonia Data at Major Clinical Microbiology Meetings
May 14 – Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial
May 07 – Curetis Launches Unyvero™ i60 Implant and Tissue Infection Cartridge in Europe
Apr 23 – New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application
Mar 27 – Curetis Obtains Key Patent for Unyvero™ Technology
Mar 04 – Curetis Prepares Launch of Second Unyvero™ Application
Oct 30 – Curetis Receives Clearance for Unyvero™ System and Pneumonia Application in Russia and Serbia
Oct 22 – Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections
Oct 09 – Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application
Sep 18 – Curetis and Mediphos to Sponsor Expert Discussion on the Future of Infectious Diseases Testing
Sep 04 – Curetis to Present Clinical Unyvero™ Data at Major Scientific Conferences
Jun 09 – Curetis beginnt multizentrische Unyvero™ Studie in Europa
Apr 22 – Curetis raises EUR 12.5 million in Series B round led by new investor HBM Partners
Apr 17 – Curetis to Present Clinical Unyvero™ Data at ECCMID 2013 in Berlin
Mar 06 – Curetis AG Strengthens Commercial Team and Expands Distribution Network
Dec 06 – Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
Oct 09 – Curetis Completes Enrollment for its EU Trial As Planned
Sep 27 – Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
Sep 26 – Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands
Sep 20 – Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge
Sep 19 – Curetis AG to Present Its Unyvero™ Solution at DGHM Conference
trial of its antibiotic solithromycin (CEM-101)
Aug 09 – Cempra to use Curetis’ Unyvero™ solution in its Phase III
Jul 18 – Curetis AG Signs Distribution Deal in Middle East with ATC
May 14 – Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization
Mar 20 – Curetis AG to Present Its Unyvero™ System for Pneumonia Diagnostics
Feb 16 – Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics
Upcoming Events 2020
Louisville, KY
Booth #141A